US-based Virtual Incision has secured an $18m Series B funding for the development of miniaturised surgical robots.
Led by Sinopharm Capital and Bluestem Capital, the funding round involved additional investors such as PrairieGold Venture Partners.
Virtual Incision intends to use the funds to support the 510(k) premarket notification submission for its next-generation miniaturised robotically assisted surgical device (RASD) to the US Food and Drug Administration (FDA).
